Abstract
Infections are a major complication in patients with acute myeloid leukemia undergoing intensive chemotherapy. They remain a major cause of therapy-associated morbidity and mortality, and represent a frequent cause of treatment withdrawal. An analysis of the medical charts of 459 younger adults included in the multicenter Acute Leukemia French Association (ALFA)-9802 trial showed that 1369 febrile episodes occurred among the 459 registered patients, including fever without identifiable source (23%) and clinically or microbiologically documented infections (77%). Bloodstream infections occurred in 314 episodes, including 129 documented episodes with Gram-positive and 96 with Gram-negative pathogens. Pulmonary infection was diagnosed in 144/1054 documented infectious episodes (14%). Invasive fungal infection was probable or proven in 116 patients. In all, 15 patients died of infection-associated complications, of whom seven died during early induction therapy, one during salvage therapy and seven during consolidation therapy. Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia.
| Original language | English |
|---|---|
| Pages (from-to) | 1068-1076 |
| Number of pages | 9 |
| Journal | Leukemia and Lymphoma |
| Volume | 53 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Jun 2012 |
Keywords
- Acute myeloid leukemia
- Aspergillosis
- Chemotherapy
- Infection
- Prognosis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Leukemia and Lymphoma, Vol. 53, No. 6, 01.06.2012, p. 1068-1076.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Infectious complications in adult acute myeloid leukemia
T2 - Analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
AU - Cannas, Giovanna
AU - Pautas, Cécile
AU - Raffoux, Emmanuel
AU - Quesnel, Bruno
AU - Botton, Stéphane De
AU - Revel, Thierry De
AU - Reman, Oumedaly
AU - Gardin, Claude
AU - Elhamri, Mohamed
AU - Boissel, Nicolas
AU - Fenaux, Pierre
AU - Michallet, Mauricette
AU - Castaigne, Sylvie
AU - Dombret, Hervé
AU - Thomas, Xavier
N1 - Funding Information: [19] Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 (Suppl. 1):S51 S59. [20] Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients:a meta-analysis. Clin Infect Dis 1996;23:795 – 805. [21] Rubio M, Palau L, Vivas JR, et al. Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994;15:101 – 104. [22] Rabbat A, Chaoui D, Lefebvre A, et al. Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications? Leukemia 2008;22:1361 – 1367. [23] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813 – 1821. [24] Gerson SL, Talbot GH, Hurwitz S,et al. Prolonged granolucytopenia: the major risk factor for invasive aspergillosis in patients with acute leukaemia. Ann Intern Med 1984;100:345 – 357. [25] Van Gool R. The cost of treating systemic fungal infections. Drugs 2001;61(Suppl. 1):49 – 56. [26] Martino R, Lopez R, Sureda A, et al. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemotherapy: a single center experience and review of the literature. Haematologica 1997;82:297 – 304. [27] Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435 – 1442. [28] Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408 – 415. [29] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327 – 360. [30] Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010;95:1762 – 1768. [31] Sonis ST. Oral complications of cancer therapy. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 2nd ed. Philadelphia: JB Lippincott; 1985. pp 2014 – 2021. [32] Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007;18:183 – 189. [33] Gorschl ü ter M, Mey U, Strehl J, et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006;6:35. [34] Wolfson JS, Sober AJ. Dermatologic manifestations of infection in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach of infection in the compromised host. 2nd ed. New York: Plenum Medical; 1986. pp 115 – 130. [35] Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML 10). Br J Haematol 1999;106:436 – 444. [36] Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72 – 77. [37] Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471 – 5489. [38] Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348 – 359. [39] Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977 – 987. [40] Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161 – 1170.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Infections are a major complication in patients with acute myeloid leukemia undergoing intensive chemotherapy. They remain a major cause of therapy-associated morbidity and mortality, and represent a frequent cause of treatment withdrawal. An analysis of the medical charts of 459 younger adults included in the multicenter Acute Leukemia French Association (ALFA)-9802 trial showed that 1369 febrile episodes occurred among the 459 registered patients, including fever without identifiable source (23%) and clinically or microbiologically documented infections (77%). Bloodstream infections occurred in 314 episodes, including 129 documented episodes with Gram-positive and 96 with Gram-negative pathogens. Pulmonary infection was diagnosed in 144/1054 documented infectious episodes (14%). Invasive fungal infection was probable or proven in 116 patients. In all, 15 patients died of infection-associated complications, of whom seven died during early induction therapy, one during salvage therapy and seven during consolidation therapy. Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia.
AB - Infections are a major complication in patients with acute myeloid leukemia undergoing intensive chemotherapy. They remain a major cause of therapy-associated morbidity and mortality, and represent a frequent cause of treatment withdrawal. An analysis of the medical charts of 459 younger adults included in the multicenter Acute Leukemia French Association (ALFA)-9802 trial showed that 1369 febrile episodes occurred among the 459 registered patients, including fever without identifiable source (23%) and clinically or microbiologically documented infections (77%). Bloodstream infections occurred in 314 episodes, including 129 documented episodes with Gram-positive and 96 with Gram-negative pathogens. Pulmonary infection was diagnosed in 144/1054 documented infectious episodes (14%). Invasive fungal infection was probable or proven in 116 patients. In all, 15 patients died of infection-associated complications, of whom seven died during early induction therapy, one during salvage therapy and seven during consolidation therapy. Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia.
KW - Acute myeloid leukemia
KW - Aspergillosis
KW - Chemotherapy
KW - Infection
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84861372982&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.636812
DO - 10.3109/10428194.2011.636812
M3 - Article
C2 - 22145959
AN - SCOPUS:84861372982
SN - 1042-8194
VL - 53
SP - 1068
EP - 1076
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -